Merck + Co., Inc.

Merial Limited

Dennis M Schmatz

Sandra J Rattray

Anne M Gurnett

Paul A Liberator

Robert E Schwartz

Georgianna S Harris

Robert W Myers

Robert Donald

Paula M Dulski

Tesfaye Biftu

Anne M Gumett

David A Claremon

Nigel J Liverton

Matthew J Wyvratt

Michael H Fisher

Otto D Hensens

Steven L Colletti

James B Doherty

Jerrold M Liesch

Gerald F Bills

Peter T Meinke

XiaoXia Qian

George M Garrity

Raymond F White

Richard Berger

Kenneth E Wilson

Charles J McIntyre

Anne W Dombrowski

Henry Joshua

Sagrario M Del Val

Gui-Bai Liang

Jack L Smith

Jan S Tkacz

Frank L VanMiddlesworth

Wendy S Horn

Richard Beresis

Richard K Jansson

Stefan Galuska

Jennifer Nielsen-Kahn

Mark Rattray

Mary Nallin

Mervyn J Turner

Peter K Murray

Carmen Diaz

Theresa W Ku

Dennis D Feng

Ernest W Kovacs

Marcia M Zweerink

Mark S Crane

Ethel B Jacobson

Balbir S Bhogal

Michael C Justice

Ming-Jo Hsu

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.

Toxoplasma gondii cylclic GMP dependent protein kinase G as a chemotherapeutic target for antiprotozoal agents

Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidial agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s). 

Antiprotozoal imidazopyridine compounds

The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated fromand. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such asand

[object Object]

Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis 

(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds

Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agents

Polynucleotide encoding eimeria tenella cGMP dependent protein kinase

Disclosed is a method for controlling phytopathogenic fungi using pure strains of ATCC 74386 and fungus ATCC 74387. Further, methods of producing a sordarin compound are disclosed. The method includes cultivating each strain separately in a nutrient medium containing assimilable sources of carbon and nitrogen and recovering the compound. A sordarin compound of formula I is also disclosed. Also an antifungal composition containing a sordarin compound is also disclosed.

Rosellinia subiculata ATCC 74386 and fungus ATCC 74387 for producing sordarin compounds for fungi control

Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.

Histone deacetylase as target for antiprotozoal agents

Inhibition of protein elongation factor 2 provides a target for identifying potential antifungal and antiparasitic compounds. EF2 inhibitors are useful as therapeutic agents against fungal and parasitic infections.

Protein elongation factor 2 as a target for antifungal and antiparasitic

The present invention provides novel cyclic tetrapeptides useful in the treatment or prevention of protozoal diseases; in particular, the novel compounds are active against the causative pathogens in malaria, toxoplasmosis, and coccidiosis. The invention also relates to the use of known compounds which are histone deacetylase inhibitors as antiprotozoal agents.

Antiprotozoal cyclic tetrapeptides

A cyclohexapeptide base which is the nucleus of closely related antibiotics obtained by culturing Zalerion arboricola and its salts are described. They are useful intermediates for the preparation of new semisynthetic compounds having antimicrobial activity.

Cyclohexapeptide compound

An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.

Antibiotic cyclopeptide fermentation product

A method for the treatment of Pneumocystis carinii, the causative agent of pneumonia of particular severity to immune compromised patients such as those with acquired immune deficiency syndrome (AIDS), by administering a lipophilic cyclohexapeptide compound of the general formula ##STR1## wherein the R groups are fully defined in the text, is described. Compositions suitable for the treatment of P. carinii are also disclosed.

Method for the control of pneumocystis carinii

Growing community of inventors

Cranford, NJ, United States of America

Dennis M Schmatz